Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen‐specific basophil response; a real‐life, nonrandomized controlled study

Zidarn, Mihaela; Košnik, Mitja; Šilar, Mira; Bajrović, Nissera; Korosec, Petar

doi:10.1111/all.12581

Cited by 44 publications

(35 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These contrasting findings may be partly explained by the route of immunotherapy, with SLIT being possibly less effective in inhibiting basophils than SCIT. Several studies show that basophil activation decreases after AIT, not only at the level of CD63 or CD203c, but also as measured by decreased DAO and increased CD107a . One study using DAO has shown persistent basophil suppression in four subjects 12–24 months after stopping AIT .…”

Section: Resultsmentioning

confidence: 99%

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Shamji

Kappen

Akdiş

et al. 2017

Allergy

305

367

View full text Add to dashboard Cite

Background: Allergen immunotherapy (AIT) is an effective treatment for allergic rhinoconjunctivitis (AR) with or without asthma. It is important to note that due to the complex interaction between patient, allergy triggers, symptomatology and vaccines used for AIT, some patients do not respond optimally to the treatment. Furthermore, there are no validated or generally accepted candidate biomarkers that are predictive of the clinical response to AIT. Clinical management of patients receiving AIT and efficacy in randomised controlled trials for drug development could be enhanced by predictive biomarkers. Method: The EAACI taskforce reviewed all candidate biomarkers used in clinical trials of AR patients with/without asthma in a literature review. Biomarkers were grouped into seven domains: (i) IgE (total IgE, specific IgE and sIgE/Total IgE ratio), (ii) IgG-subclasses (sIgG1, sIgG4 including SIgE/IgG4 ratio), (iii) Serum inhibitory activity for IgE (IgE-FAB and IgE-BF), (iv) Basophil activation, (v) Cytokines and Chemokines, (vi) Cellular markers (T regulatory cells, B regulatory cells and dendritic cells) and (vii) In vivo biomarkers (including provocation tests?). Results: All biomarkers were reviewed in the light of their potential advantages as well as their respective drawbacks. Unmet needs and specific recommendations on all seven domains were addressed.

show abstract

Section: Resultsmentioning

confidence: 99%

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Shamji

Kappen

Akdiş

et al. 2017

Allergy

305

367

View full text Add to dashboard Cite

show abstract

“…In subjects suffering from seasonal pollen‐allergic rhinitis, SCIT induces a strong decrease in basophil sensitivity during the updosing phase . These early changes in basophil sensitivity were shown to predict clinical outcome in the following pollen season and are maintained throughout maintenance therapy and even after treatment cessation . A protocol of preseasonal injections also reduced the basophil response .…”

Section: Biomarkers For Diagnosis and Monitoring In Ait Trialsmentioning

confidence: 99%

Novel approaches and perspectives in allergen immunotherapy

Hoffmann

Valovirta

Pfaar

et al. 2017

Allergy

View full text Add to dashboard Cite

In this review, we report on relevant current topics in allergen immunotherapy (AIT) which were broadly discussed during the first Aarhus Immunotherapy Symposium (Aarhus, Denmark) in December 2015 by leading clinicians, scientists and industry representatives in the field. The aim of this symposium was to highlight AIT-related aspects of public health, clinical efficacy evaluation, mechanisms, development of new biomarkers and an overview of novel therapeutic approaches. Allergy is a public health issue of high socioeconomic relevance, and development of evidence-based action plans to address allergy as a public health issue ought to be on national and regional agendas. The underlying mechanisms are in the focus of current research that lays the ground for innovative therapies. Standardization and harmonization of clinical endpoints in AIT trials as well as current knowledge about potential biomarkers have substantiated proof of effectiveness of this disease-modifying therapeutic option. Novel treatments such as peptide immunotherapy, intralymphatic immunotherapy and use of recombinant allergens herald a new age in which AIT may address treatment of allergy as a public health issue by reaching a large fraction of patients.Allergies have become a public health concern of pandemic proportions that affect >150 million Europeans. More alarming, their prevalence and impact are on the rise. It has been predicted that within the next few decades, up to half of the European population may at some point in their lives experience some type of allergy (1). Allergen immunotherapy (AIT) is the only Abbreviations AEC, allergen exposure

show abstract

“…(6–8) Suppression of basophil activation has been associated with immunotherapy to both environmental(9, 10) and food allergens. (1, 11–14) Historically, identification of rare cells such as basophils has been difficult with flow cytometry due to their relative scarcity (15, 16) However, wide-spread adoption of this flow cytometry-based test has been limited by the intensive nature of analysis and interpretation required for flow cytometry data by expert operators.…”

Section: Introductionmentioning

confidence: 99%

“…Measurement of antigen-induced basophil activation ex vivo has been shown to be a promising diagnostic test in many allergic disorders (6)(7)(8). Suppression of basophil activation has been associated with immunotherapy to both environmental (9,10) and food allergens (1,(11)(12)(13)(14). Historically, identification of rare cells such as basophils has been difficult with flow cytometry due to their relative scarcity (15,16).…”

Section: Introductionmentioning

confidence: 99%

Data‐driven programmatic approach to analysis of basophil activation tests

Patil

Calatroni

Schneider

et al. 2017

Cytometry Part B Clinical

View full text Add to dashboard Cite

show abstract

Sustained effect of grass pollen subcutaneous immunotherapy on suppression of allergen‐specific basophil response; a real‐life, nonrandomized controlled study

Abstract: Grass pollen immunotherapy induces sustained suppression of the allergen-specific basophil response that persists after completion of treatment and could account for long-term clinical tolerance. It also seems to be associated with persistent blocking activity of IgG antibodies.

Cited by 44 publications

References 23 publications

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Biomarkers for monitoring clinical efficacy of allergen immunotherapy for allergic rhinoconjunctivitis and allergic asthma: an EAACI Position Paper

Novel approaches and perspectives in allergen immunotherapy

Data‐driven programmatic approach to analysis of basophil activation tests

Contact Info

Product

Resources

About